awmsg logo



tipranavir (Aptivus®)


Reference No. 53

Publication date:
03/02/2011


Appraisal information

tipranavir (Aptivus®) 250 mg capsule


Company: Boehringer Ingelheim Ltd
BNF category: Infections
NMG meeting date: 17/11/2010
AWMSG meeting date: 15/12/2010
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2010
Ministerial ratification: 27/01/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tipranavir (Aptivus®) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales, for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options. Tipranavir (Aptivus®) capsules are not suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download